Aquaculture Vaccines Market

Global Aquaculture Vaccines Market Size (2024 to 2029)

The global aquaculture vaccines market is forecasted to be worth USD 371.99 million by 2029 from USD 261.05 million in 2024, registering a CAGR of 7.12% from 2024 to 2029. 

Vaccination in aquaculture is extremely important for producing healthy fish and eradicating the problems of diseases spread through seafood. The most consumed sea foods like salmon and tuna are all captured and sold through fish faring. Fish farming is a large commercial business in the seafood industry, and vaccination is an essential process to ensure consumer safety. In addition to salmon and trout, various other fish have commercial vaccines available for their production. Fish have generally shown great success with experimentally designed vaccinations based on inactivated bacterial infections. There aren't any parasite vaccines, and there aren't many commercially accessible virus vaccines. However, significant efficacy data are available for new fish vaccines, and cutting-edge technology has been used.

However, several challenges must be overcome before such vaccines can be successfully commercialized, including producing low-cost but potent adjuvants and antigens while considering environmental and regulatory considerations. (For instance, those that forbid the administration of live vaccinations.) Fish vaccines have been the subject of a substantial investigation by pharmaceutical corporations, although the literature on them is few. Furthermore, salmonids dominate the literature and the commercial focus despite making up a modest portion of the world's overall fish production.

COVID-19 has hampered the growth rate of the aquaculture vaccines market.

Disruptions in the supply chain, a drop in sales, weak demand, increased knowledge of the dangers of disease transmission from animals to humans, and operational challenges brought on by shifting regulations and policies all significantly negatively impacted the aquaculture vaccine market during the pandemic. According to the World Health Organization (WHO), the COVID-19 pandemic has affected millions of people, underscoring the significance of vaccines in reducing the transmission and risk of cross-infection. Several businesses, notably Zeotis, have upped their support in response to the Covid-19 pandemic by enhancing supply chain technology. Utilizing stock in certain market outlets was the next step, which helped cut losses brought on by the growth of the aquaculture vaccination market.

MARKET DRIVERS

The adoption of vaccines from aquaculture farmers is increasing Y-O-Y, which is anticipated to be the primary growth factor in the aquaculture vaccines market.

Due to the advancement of aquaculture vaccinations, the market is favorably developing. The introduction of new products and the enactment of various government restrictions in industrialized countries regarding the use of antibiotics in aquaculture are promoting the growth of the aquaculture vaccines market. In addition, recent and quickly advancing vaccine research to treat diseases by viruses and bacteria is predicted to be another significant driver of the market expansion. The manufacturers' current top priorities are the advancement of immunizations and their dissemination. Due to several research projects aimed at developing vaccines, the market is expected to expand.

MARKET RESTRAINTS

The growth rate of the aquaculture vaccines market is predicted to be hampered by natural factors that limit the expansion of aquatic life. The stringent guidelines during approval by the FDA and regulations required for vaccines to enter the market pose a threat to aquaculture. Additionally, the creation of vaccines is far more complex and time-consuming, which limits market expansion. 

REPORT COVERAGE

SEGMENTAL ANALYSIS

Global Aquaculture Vaccines Market Analysis By Product

Based on the product, the inactivated vaccines segment accounted for the largest share of the global aquaculture vaccines market in 2023, and the domination of this segment is anticipated to be there throughout the forecast period. The inactivated vaccine market is expanding due to its capacity to elicit potent reactions by holding onto the inactivated genomic component and its long-lasting immune response.

On the other hand, the recombinant vaccines segment is projected to experience a CAGR of 8.65% during the forecast duration. In addition, recombinant vaccines exhibit a significant resistance response and are simpler to produce in large quantities and commercially.

Global Aquaculture Vaccines Market Analysis By Route of Administration

Based on the route of administration, the injected segment is anticipated to be the most lucrative segment during the forecast period and occupied the most considerable share of the global market in 2023. The ability of injection vaccines to treat various viral and bacterial infections, in turn, fuels the segment's expansion. As a result, the forecast period is expected to have the highest immersion vaccine growth rate.

Besides, the oral segment is predicted to showcase a CAGR of 8.76% during the forecast period. Compared to other delivery methods, oral vaccination has several benefits.

Global Aquaculture Vaccines Market Analysis By Application

Due to the rise in bacterial diseases, including pseudomonas, streptococcus, vibriosis, and others, the bacterial segment is predicted to dominate the application segment. The demand for bacterial infection vaccines is the huge financial losses aquaculture experiences because of bacterial illnesses, which reflects the growth of this segment.

However, the viral segment is projected to experience the highest CAGR of 8.75% throughout the forecast period. Like bacterial aquatic diseases, viral diseases also affect fish and result in significant losses. Salmon are susceptible to viral infections such as salmon ISA virus, a salmon pancreatic disease caused by SPD virus, or IPN caused by IPNV.

REGIONAL ANALYSIS

Europe had the highest share in the global aquaculture vaccines market in 2023. Norway's position as the world's largest salmon exporter, supportive government and private-sector activities increased human concerns about antibiotic resistance, and the presence of key market participants are primarily supporting Europe to stand as the regional market leader for aquaculture vaccines. In addition, under the 7th Framework Program, the European Commission supported a large-scale collaborative project to support the aquaculture industry.

Due to the rising aquaculture industry and advancements in vaccination, Asia Pacific will likely hold a significant market position in the worldwide aquaculture vaccines market during the forecast period. Asia is home to all five major countries involved in aquaculture production. China is the most significant fish producer of crustaceans and mollusks, with a total production of 49,244,101 metric tons. However, the rising prevalence of acute hepatopancreatic necrosis, and hepatopancreatic microsporidiosis, necessitates aquatic animal healthcare treatment.

By 2026, the market for aquaculture vaccines in North America is predicted to grow. In aquaculture farming, inactivated and live vaccines are widely used to vaccinate fish. Therefore, fish growers will be in high demand for live vaccinations. Live vaccines are highly immunogenic because they can penetrate the body of a fish and cause increased immunity and adaptation responses in the host cells. In addition, the immunizations are simple to deliver via oral or subcutaneous methods. The need for live vaccinations among fish producers in the region will increase due to these factors.

Key Market Participants

Zoetis, Phibro Animal Health Corporation, Elanco, Merck & Co., Inc., KBNP, CAVAC, Kyoto Biken Laboratories, Inc., Nisseiken Co., Ltd., Vaxxinova International BV, and HIPRA are a few major companies operating in the global aquaculture vaccines market profiled in this report.

Recent Market Developments

• Elanco announced to relocate its global headquarters to Indiana, United States, in December 2020. This aligned with Elanco's Innovation, Portfolio, and Productivity (IPP) strategy and helped develop a center of excellence for the company's future footprint consolidation.
• Phibro Animal Health Corporation acquired the assets of KoVax Ltd on December 6th, 2018.
• PharmaQ, a vaccine manufacturer, bought Nordland Sett Vaks, a Norwegian company, in 2017 to extend its aquaculture vaccine product range.

DETAILED SEGMENTATION OF THE GLOBAL AQUACULTURE VACCINES MARKET INCLUDED IN THIS REPORT

This research report on the global aquaculture vaccines market has been segmented and sub-segmented into the following categories based on product, route of administration, application & region.

By Product

• Attenuated Live Vaccines
• Inactivated Vaccines
• Subunit Vaccines
• DNA Vaccines
• Recombinant Vaccines

By Route of Administration

• Oral
• Injected
• Immersion & Spray

By Application

• Bacterial
• Viral
• Parasitic

By Region

• North America
• Europe 
• Asia-Pacific
• Latin America
• Middle East and Africa